OnabotulinumtoxinA in chronic migraine: is the response dose dependent?

被引:0
作者
Ali Zandieh
Fred Michael Cutrer
机构
[1] University of Wisconsin,Department of Neurology
[2] Department of Neurology,undefined
[3] Mayo Clinic,undefined
来源
BMC Neurology | / 22卷
关键词
Headache; Chronic migraine; OnabotulinumtoxinA; Migraine treatment; Dose response;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 202 条
[1]  
Finley CR(2018)What are the most common conditions in primary care? systematic review Can Fam Physician 64 832-840
[2]  
Chan DS(2018)Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017 Lancet 392 1789-1858
[3]  
Garrison S(2010)The epidemiology of primary headache disorders Semin Neurol 30 107-119
[4]  
Korownyk C(1999)Kaplan Award 1998. Epidemiology of chronic daily headache in the general population Headache 39 190-196
[5]  
Kolber MR(1998)Prevalence of frequent headache in a population sample Headache 38 497-506
[6]  
Campbell S(2016)Impact of depression and anxiety on burden and management of episodic and chronic headaches - a cross-sectional multicentre study in eight Austrian headache centres J Headache Pain 17 15-155
[7]  
Eurich DT(2003)Chronic daily headache: is analgesic overuse a cause or a consequence? Neurology 61 154-483
[8]  
Lindblad AJ(2004)Medication-overuse headache: a worldwide problem Lancet Neurol 3 475-88
[9]  
Vandermeer B(2006)Efficacy and safety of a single botulinum type a toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study Pain 125 82-283
[10]  
Allan GM(2008)Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain Ann Neurol 64 274-936